Chun-Hang Tang

机构：Astellas Pharma (United Kingdom) · ORCID：0000-0002-3839-221X

发表论文 4 篇 · 总被引 267 次 · h-index 2

代表论文

• A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis (2021 · Kidney International · 被引 214)
• Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population (2022 · American Journal of Kidney Diseases · 被引 51)
• Clinical and Molecular Effect of the Anti– IL ‐18 Antibody Aletekitug in Adults With Atopic Dermatitis (2025 · Allergy · 被引 2)
• HIGHLIGHT 1: A randomized, placebo-controlled, double-blind, phase 3 clinical study to investigate the efficacy and safety of fezolinetant for treatment of moderate to severe vasomotor symptoms (hot flashes) in women with stage 0 to 3 hormone receptor–positive breast cancer who are receiving adjuvant endocrine therapy. (2026 · Journal of Clinical Oncology)